Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  guadecitabine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-8 of 8 for your search:
Start Over
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGI-110-04, NCT02348489
Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1369, NA_00085870, NCT01896856
4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 70
Sponsor: Other
Protocol IDs: 2013-0843, NCI-2014-00981, NCT02096055
SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0901, NCI-2014-02377, NCT02131597
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J13138, NA_00087578, NCT01966289
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 343-14-001, NCT02293993
Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IUCRO-0508, NCT02429466
Start Over